Cargando…

Brain metastasis from hepatocellular carcinoma: the role of surgery as a prognostic factor

BACKGROUND: The incidence of brain metastasis from hepatocellular carcinoma (HCC) is expected to increase as a result of prolonged survival due to the recent advances in HCC treatment. However, there is no definite treatment strategy for brain metastasis from HCC mainly due to its rarity and dismal...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Moon-Soo, Moon, Kyung-Sub, Lee, Kyung-Hwa, Cho, Sung-Bum, Lim, Sa-Hoe, Jang, Woo-Youl, Jung, Tae-Young, Kim, In-Young, Jung, Shin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3879022/
https://www.ncbi.nlm.nih.gov/pubmed/24289477
http://dx.doi.org/10.1186/1471-2407-13-567
_version_ 1782297905647845376
author Han, Moon-Soo
Moon, Kyung-Sub
Lee, Kyung-Hwa
Cho, Sung-Bum
Lim, Sa-Hoe
Jang, Woo-Youl
Jung, Tae-Young
Kim, In-Young
Jung, Shin
author_facet Han, Moon-Soo
Moon, Kyung-Sub
Lee, Kyung-Hwa
Cho, Sung-Bum
Lim, Sa-Hoe
Jang, Woo-Youl
Jung, Tae-Young
Kim, In-Young
Jung, Shin
author_sort Han, Moon-Soo
collection PubMed
description BACKGROUND: The incidence of brain metastasis from hepatocellular carcinoma (HCC) is expected to increase as a result of prolonged survival due to the recent advances in HCC treatment. However, there is no definite treatment strategy for brain metastasis from HCC mainly due to its rarity and dismal prognosis. To provide helpful recommendations in treatment of brain metastasis from HCC, the authors aimed to identify prognostic factors that influence survival rates with a review of the recently published data. METHODS: Thirty-three cases of brain metastasis, whose incidence was 0.65%, were selected from a total of 5015 HCC patients and reviewed retrospectively in terms of clinical and radiological features. RESULTS: Median overall survival time after diagnosis of brain metastasis was 10.4 weeks (95% confidence interval [CI], 5.1-15.7 weeks) with 1-, 6- and 12-month survival rates, of 79%, 24% and 6%, respectively. Median survival of the patients treated with surgical resection or surgical resection followed by whole-brain radiation therapy (WBRT) (25.3 weeks; range, 15.8-34.8 weeks) was longer than that of the patients treated with gamma knife surgery (GKS), WBRT, or GKS followed by WBRT (10.4 weeks; range, 7.5-13.3 weeks) as well as that of patients treated with only steroids (1 week; range, 0.0-3.3 weeks) (p < 0.001). Child-Pugh’s classification A group had a longer median survival time than Child-Pugh’s classification B or C group (14.4 weeks vs 8.4 weeks, p = 0.038). RPA class I & II group had also a longer median survival time than RPA class III group did (13.4 weeks vs 2.4 weeks, p = 0.001). Surgical resection (hazard ratio [HR] 0.23, 95% CI 0.08-0.66, p = 0.006) and good liver function at the time of brain metastasis (HR 0.25, 95% CI 0.09-0.69, p = 0.007) were found to be the powerful prognostic factors for favorable survival in the multivariate analysis. In addition, presence of intratumoral hemorrhage was a statistically significant prognostic factor for survival. CONCLUSION: Although HCC patients with brain metastasis showed a very dismal prognosis, surgical intervention was shown to lead to relative prolongation of the survival time, especially in those with preserved hepatic function.
format Online
Article
Text
id pubmed-3879022
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-38790222014-01-03 Brain metastasis from hepatocellular carcinoma: the role of surgery as a prognostic factor Han, Moon-Soo Moon, Kyung-Sub Lee, Kyung-Hwa Cho, Sung-Bum Lim, Sa-Hoe Jang, Woo-Youl Jung, Tae-Young Kim, In-Young Jung, Shin BMC Cancer Research Article BACKGROUND: The incidence of brain metastasis from hepatocellular carcinoma (HCC) is expected to increase as a result of prolonged survival due to the recent advances in HCC treatment. However, there is no definite treatment strategy for brain metastasis from HCC mainly due to its rarity and dismal prognosis. To provide helpful recommendations in treatment of brain metastasis from HCC, the authors aimed to identify prognostic factors that influence survival rates with a review of the recently published data. METHODS: Thirty-three cases of brain metastasis, whose incidence was 0.65%, were selected from a total of 5015 HCC patients and reviewed retrospectively in terms of clinical and radiological features. RESULTS: Median overall survival time after diagnosis of brain metastasis was 10.4 weeks (95% confidence interval [CI], 5.1-15.7 weeks) with 1-, 6- and 12-month survival rates, of 79%, 24% and 6%, respectively. Median survival of the patients treated with surgical resection or surgical resection followed by whole-brain radiation therapy (WBRT) (25.3 weeks; range, 15.8-34.8 weeks) was longer than that of the patients treated with gamma knife surgery (GKS), WBRT, or GKS followed by WBRT (10.4 weeks; range, 7.5-13.3 weeks) as well as that of patients treated with only steroids (1 week; range, 0.0-3.3 weeks) (p < 0.001). Child-Pugh’s classification A group had a longer median survival time than Child-Pugh’s classification B or C group (14.4 weeks vs 8.4 weeks, p = 0.038). RPA class I & II group had also a longer median survival time than RPA class III group did (13.4 weeks vs 2.4 weeks, p = 0.001). Surgical resection (hazard ratio [HR] 0.23, 95% CI 0.08-0.66, p = 0.006) and good liver function at the time of brain metastasis (HR 0.25, 95% CI 0.09-0.69, p = 0.007) were found to be the powerful prognostic factors for favorable survival in the multivariate analysis. In addition, presence of intratumoral hemorrhage was a statistically significant prognostic factor for survival. CONCLUSION: Although HCC patients with brain metastasis showed a very dismal prognosis, surgical intervention was shown to lead to relative prolongation of the survival time, especially in those with preserved hepatic function. BioMed Central 2013-12-01 /pmc/articles/PMC3879022/ /pubmed/24289477 http://dx.doi.org/10.1186/1471-2407-13-567 Text en Copyright © 2013 Han et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Han, Moon-Soo
Moon, Kyung-Sub
Lee, Kyung-Hwa
Cho, Sung-Bum
Lim, Sa-Hoe
Jang, Woo-Youl
Jung, Tae-Young
Kim, In-Young
Jung, Shin
Brain metastasis from hepatocellular carcinoma: the role of surgery as a prognostic factor
title Brain metastasis from hepatocellular carcinoma: the role of surgery as a prognostic factor
title_full Brain metastasis from hepatocellular carcinoma: the role of surgery as a prognostic factor
title_fullStr Brain metastasis from hepatocellular carcinoma: the role of surgery as a prognostic factor
title_full_unstemmed Brain metastasis from hepatocellular carcinoma: the role of surgery as a prognostic factor
title_short Brain metastasis from hepatocellular carcinoma: the role of surgery as a prognostic factor
title_sort brain metastasis from hepatocellular carcinoma: the role of surgery as a prognostic factor
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3879022/
https://www.ncbi.nlm.nih.gov/pubmed/24289477
http://dx.doi.org/10.1186/1471-2407-13-567
work_keys_str_mv AT hanmoonsoo brainmetastasisfromhepatocellularcarcinomatheroleofsurgeryasaprognosticfactor
AT moonkyungsub brainmetastasisfromhepatocellularcarcinomatheroleofsurgeryasaprognosticfactor
AT leekyunghwa brainmetastasisfromhepatocellularcarcinomatheroleofsurgeryasaprognosticfactor
AT chosungbum brainmetastasisfromhepatocellularcarcinomatheroleofsurgeryasaprognosticfactor
AT limsahoe brainmetastasisfromhepatocellularcarcinomatheroleofsurgeryasaprognosticfactor
AT jangwooyoul brainmetastasisfromhepatocellularcarcinomatheroleofsurgeryasaprognosticfactor
AT jungtaeyoung brainmetastasisfromhepatocellularcarcinomatheroleofsurgeryasaprognosticfactor
AT kiminyoung brainmetastasisfromhepatocellularcarcinomatheroleofsurgeryasaprognosticfactor
AT jungshin brainmetastasisfromhepatocellularcarcinomatheroleofsurgeryasaprognosticfactor